The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

第15届医博会期间，同写意生物医药新基建链盟将举办ADC专场，邀请抗体/ADC研发端、生产端和供应链端的企业负责人与会深度交流，帮助行业优化和提升生物药创新生态链。

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market ...

在抗肿瘤药物研发的复杂舞台上，Blenrep的故事宛如一出跌宕起伏的戏剧。曾几何时，这款靶向BCMA的抗体药物被视为GSK重返癌症领域的利器，然而，市场的残酷和临床试验的不确定性让它经历了一波三折的命运。对于许多人来说，Blenrep的退市似乎意味着它的终章，但就在GSK即将放弃时，新的希望又重新燃起。在临床试验DREAMM-7的中期分析显示出积极结果时，这款产品又重新回到了公众的视野中。

Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory ...